Track record · closed signal

Novavax Inc (NVAX) — closed signal from May 6, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on August 4, 2026 — -10.1% at the close.

Predicted vs. what happened

NVAX price · publication thesis → realized outcomesplit-adjusted
$8.53 Published $10.57 Target $7.66 Window close $11.61 Peak
$7.90 – $8.70Entry zone — fair-value band
$8.53Published — price the day we called it
$10.57Target — the price the thesis aimed for
$11.61Peak — highest point inside the window, not a realized return
$7.66Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 2 days.

At window close
-10.1%
realized, from the publication price to the last close inside the window
Peak gain
+36.1%
peak, from the publication price — not a realized return
S&P 500, same window
+5.4%
SPY over the identical days, dividend-adjusted
Window close
$7.66
last close inside the window, ended August 4, 2026
Peak price
$11.61
peak on May 27, 2026 — not a realized return
Days to target
2

The thesis — published May 6, 2026

Predicted growth
+24%
over the measurement window
Target price
$10.57
the price the thesis aimed for
Entry zone
$7.90 – $8.70
the fair-value band we waited for
Price at publication
$8.53
published May 6, 2026
Confidence
68%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Novavax is a risky but potentially high-reward biotech story. A shift toward licensing and upcoming vaccine results could quickly improve the outlook, and the stock looks cheap enough to attract interest. However, drug-development swings, many traders betting against the stock, and uneven earnings make this a short-term speculation best treated cautiously.

Primary drivers

  • Licensing shift can cut the company's cash needs and financial risk
  • Positive vaccine results can change how investors value the company
  • A stronger balance sheet helps fund development through trials
  • High short interest can make positive news produce large price moves

How it played out

NVAX: target reached in 2 days

Lyra published NVAX at $8.53 on May 6, with expected growth of 24% and a $10.57 target. The thesis pointed to licensing as a way to reduce cash needs, positive vaccine results, a stronger balance sheet, and high short interest. It also described the stock as risky because of drug-development swings and uneven earnings.

The price reached the target in 2 days. It later peaked at $11.61 on May 27, a gain of 36.1%. By the end of the window on August 4, it had fallen to $7.66. The short-term thesis played out, although the gain did not hold through the full window.

What happened during the window

On May 6, 2026, Novavax reported first-quarter total revenue of $140 million and reiterated its 2026 revenue framework.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVAX signals